Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
12.45 USD | +0.73% | +2.47% | -17.50% |
Sales 2024 * | 61.91M 84.62M | Sales 2025 * | 28.63M 39.14M | Capitalization | 403M 552M |
---|---|---|---|---|---|
Net income 2024 * | -81M -111M | Net income 2025 * | -139M -190M | EV / Sales 2024 * | 5.15 x |
Net cash position 2024 * | 84.48M 115M | Net cash position 2025 * | 110M 150M | EV / Sales 2025 * | 10.3 x |
P/E ratio 2024 * |
-5.44
x | P/E ratio 2025 * |
-3.79
x | Employees | 159 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 82.21% |
Latest transcript on Entrada Therapeutics, Inc.
1 day | +0.73% | ||
1 week | +2.47% | ||
Current month | -12.14% | ||
1 month | -13.24% | ||
3 months | -16.05% | ||
6 months | -14.14% | ||
Current year | -17.50% |
Managers | Title | Age | Since |
---|---|---|---|
Dipal Doshi
CEO | Chief Executive Officer | 48 | 17-07-31 |
Kory Wentworth
DFI | Director of Finance/CFO | 45 | 20-10-31 |
Nathan Dowden
PSD | President | 54 | 19-11-03 |
Members of the board | Title | Age | Since |
---|---|---|---|
Peter Kim
BRD | Director/Board Member | 65 | 20-11-30 |
Mary Thistle
BRD | Director/Board Member | 64 | 21-05-03 |
Gina Chapman
BRD | Director/Board Member | 57 | 23-08-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.00% | 34 M€ | +2.14% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-04-26 | 12.45 | +0.73% | 25,818 |
24-04-25 | 12.36 | -0.56% | 84,124 |
24-04-24 | 12.43 | -3.57% | 38,559 |
24-04-23 | 12.89 | -1.60% | 43,975 |
24-04-22 | 13.1 | +7.82% | 119,085 |
Delayed Quote Nasdaq, April 26, 2024 at 04:00 pm
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-17.50% | 403M | |
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.73B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |
- Stock Market
- Equities
- TRDA Stock